Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-?-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)

WESTON, Fla., Oct. 16, 2018 /PRNewswire/ -- Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced today Notice of Allowance for two U.S. patent applications covering hydroxypropyl-?-cyclodextrin (HP?CD) for use in renal diseases (licensed from L&F Research LLC). Variant's HP?CD pipeline includes VAR 200, a phase 2a-ready asset in development for FSGS; VAR 300 for Alport Syndrome, and VAR 400 for Diabetic Kidney Disease.

The claims in U.S. patent application 14/967,831 relate to use of HP?CD to treat FSGS and Alport Syndrome, reduce progression of FSGS, and reduce recurrence of FSGS following transplant.

The claims in U.S. patent application 14/391,236 relate to use of HP?CD or its derivatives to treat or reduce progression of Diabetic Kidney Disease.

"These Notices of Allowance strengthen the value of Variant's pipeline with intellectual property protection, and they highlight our progress toward development and commercialization of novel drug therapies to optimize patient outcomes," stated Stephen C. Glover, Variant's Co-founder, Chairman and Chief Executive Officer. "Through ongoing research and development, we will continue to advance our intellectual property estate by pursuing broader and/or modified scopes of protection." 

About Variant

Variant Pharmaceuticals, a clinical stage orphan drug company focusing on restoring health and transforming the lives of patients with rare diseases through innovation, was established in 2014, with the mission to become a leading orphan drug company.  Our evolving product pipeline is targeted to the $100+ billion orphan drug market. Our lead drug candidate is 2-hydroxypropyl-?-cyclodextrin (2HP?CD) for chronic treatment of two rare kidney indications, Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS), which have an addressable market greater than $3.5 Billion.   

SOURCE Variant Pharmaceuticals, Inc.